Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape

Phase III Data Seen As Underwhelming

Executive Summary

The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption

You may also be interested in...



Praxis Moves Away From Depression With Surprising Phase II/III Failure

With GABA-A modulator PRAX-114 missing all endpoints in a monotherapy study, Praxis will cease development of that drug and focus on its candidates for essential tremor and epilepsy.

Sage/Biogen Zuranolone Study Shows More Efficacy, But Higher Toxicity

Data from SHORELINE’s 50mg cohort sparked mixed opinions from analysts, with some suggesting they still showed a risk-benefit profile that could challenge the drug commercially.

Sage/Biogen Delay Zuranolone Filing, Commercial Path Remains Unclear

The companies will seek approval for zuranolone in MDD second-half 2022 and in PPD in first-half 2023, but that also means launch will probably happen second-half 2023.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel